Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. (August 2020)

• Record Type: Journal Article
• Authors: Zhao, Dan; Mambetsariev, Isa; Li, Haiqing; Chen, Chen; Fricke, Jeremy; Fann, Patricia; Kulkarni, Prakash; Xing, Yan; Lee, Peter P.; Bild, Andrea; Massarelli, Erminia; Koczywas, Marianna; Reckamp, Karen; Salgia, Ravi
• Is Part Of: Lung cancer. Volume 146(2020)
• Page Start: 174
• Page End: 181
• Publication Date: 2020-08
• Subjects: Lung cancer -- Molecular -- Next-generation sequencing (NGS) -- Immune checkpoint inhibitors -- TET2 -- FANCA -- PD-L1 -- TMB -- Immunotherapy; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2020.05.025
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: 346 Lung Cancer patients including next generation sequencing data were analyzed. EGFR mutations were associated with shorter overall survival. PD-L1 ≥ 50% was associated with longer overall survival. TET2 muations was associated with longer overall survival. TET2 mutations were mutually exclusive with FANCA gene mutations. Abstract: Objectives: Immune checkpoint inhibitors (ICIs) have changed the landscape of lung cancer therapy. However significant proportions of patients have primary or acquired resistance to ICIs. Molecular characterization is critical for patient selection and overcoming resistance to checkpoint inhibitors. The purpose of this study is to investigate the molecular characteristics associated with ICIs outcomes in advanced non-small cell lung cancer (NSCLC) patients. Materials and methods: All advanced stage NSCLC patients at City of Hope who received ICIs (pembrolizumab, nivolumab, atezolizumab, and durvalumab) were identified retrospectively. Overall survival (OS, from the start of the ICIs), Pathology and information on genomic alterations (GAs) including next-generation sequencing (NGS) data, tumor mutation burden (TMB), and Programmed death-ligand 1 (PD-L1) levels were collected. Chi-square and Fisher's exact test, Log-rank test were used for comparison of demographics, and survival curves respectively. Univariate and multivariate COX proportional hazards model was used for survival analysis. Results: 346 NSCLC patients were identified. Univariate and multivariate analysis found the association of OS with PD-L1 level ≥50% (Hazard ratio [HR], 0.19; 95% confidence interval [CI], 0.06−0.59; P < 0.01), EGFR (HR 7.38; 95% CI, 1.15–47.42; P < 0.05), and TET2 (HR 0.15; 95% CI, 0.03−0.90; P < 0.05). The median OS was not reached [NR] for the 12 patients who had genomic alterations (GAs) in TET2 (12/108, 11%) versus (vs) 11.5 months in TET2 negative patients (98/108, 89%). Interestingly, GAs in TET2 and FANCA were mutually exclusive and patients who had GAs in FANCA gene (6%) had shorter OS (5.5 months vs 14.5 months, Log-rank test, P < 0.05). Conclusions: We described the clinical and molecular features of NSCLC patients treated with ICIs. The association of GAs in TET2 with longer OS and its mutual exclusivity with FANCA GAs were insightful for developing novel therapeutic strategies to improve ICIs outcomes in NSCLC.